When Amylin Pharmaceuticals Inc. won approval of its second diabetes drug in as many months, Byetta (exenatide), the company's stock - rather than skyrocketing, as likely would have happened in the old days - fell 6 percent.
In reporting positive results from a Phase III study of Oravescent fentanyl, Cephalon Inc. said it is on track to submit a new drug application to the FDA next quarter. (BioWorld Today)
RSS